Han Shaoli, Liu Lei, Xu Fengyan, Chen Shuang, Yuan Weiguang, Fu Zhenkun, Li Dalin, Li Dianjun
Department of Immunology.
Department of Immunology; College of Bioinformatics Science and Technology.
Chin J Cancer Res. 2016 Aug;28(4):435-43. doi: 10.21147/j.issn.1000-9604.2016.04.07.
The inhibition of the neovascularization in tumors is a potential therapeutic target of cancer. Vascular endothelial growth inhibitor (VEGI) is a member of the TNF superfamily which has the ability to suppress the formation of new vessels in tumors. In order to study the association between VEGI gene polymorphisms and breast cancer risk, a case-control study was conducted in Chinese Han women in Northeast China.
Our study involved 708 female breast cancer patients and 685 healthy volunteers. Four SNPs of VEGI gene were analyzed through the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The association between VEGI gene polymorphisms and breast cancer risk was analyzed in our study. The relation between VEGI gene variants and clinical features of breast cancer including lymph node (LN) metastasis, estrogen receptor (ER), progestrogen receptor (PR), tumor protein 53 (p53), human epidermal growth factor receptor 2 (Her-2) and triple negative (ER-/PR-/Her-2-) status was analyzed as well.
We found that the CT genotype and T allele of rs6478106 were more frequent in patients than in controls. There was also a statistical difference in the distribution of Crs6478106Grs4263839 haplotype between patients and controls. In addition, SNP rs6478106 and rs4979462 were related with the Her-2 status.
Our results suggest that VEGI gene variants may be related to the breast cancer risk and the clinical features of breast cancer in Chinese Han women in Northeast China.
抑制肿瘤血管生成是癌症潜在的治疗靶点。血管内皮生长抑制因子（VEGI）是肿瘤坏死因子超家族成员，具有抑制肿瘤新血管形成的能力。为研究VEGI基因多态性与乳腺癌风险的关系，在中国东北汉族女性中开展了一项病例对照研究。
本研究纳入708例女性乳腺癌患者和685例健康志愿者。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法分析VEGI基因的4个单核苷酸多态性（SNP）。分析VEGI基因多态性与乳腺癌风险的关联。同时分析VEGI基因变异与乳腺癌临床特征（包括淋巴结转移、雌激素受体、孕激素受体、肿瘤蛋白53、人表皮生长因子受体2和三阴性状态）的关系。
我们发现，rs6478106的CT基因型和T等位基因在患者中的频率高于对照组。患者与对照组之间Crs6478106Grs4263839单倍型的分布也存在统计学差异。此外，SNP rs6478106和rs4979462与Her-2状态相关。
我们的结果表明，VEGI基因变异可能与中国东北汉族女性的乳腺癌风险及乳腺癌临床特征有关。
